Association of Obesity and Kidney Function Decline among Non-Diabetic Adults with eGFR > 60 ml/min/1.73m2: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)

DOI: 10.4236/ojemd.2013.32016   PDF   HTML     3,595 Downloads   6,091 Views   Citations


Background: Obesity is associated with higher end-stage renal disease incidence, but associations with earlier forms of kidney disease remain incompletely characterized. Methods: We studied the association of body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) with rapid kidney function decline and incident chronic kidney disease in 4573 non-diabetic adults with eGFR ≥ 60 ml/min/1.73m2 at baseline from longitudinal Multi-Ethnic Study of Atherosclerosis cohort. Kidney function was estimated by creatinine and cystatin C. Multivariate analysis was adjusted for age, race, baseline eGFR, and hypertension. Results: Mean age was 60 years old, BMI 28 kg/m2, baseline eGFRCr 82 and eGFRCys 95 ml/min/1.73m2. Over 5 years of follow up, 25% experienced rapid decline in renal function by eGFRCr and 22% by eGFRCys. Incident chronic kidney disease (CKD) developed in 3.3% by eGFRCys, 11% by eGFRCr, and 2.4% by both makers. Compared to persons with BMI < 25, overweight (BMI 25 - 30) persons had the lowest risk of rapid decline by eGFRCr (0.84, 0.71 - 0.99). In contrast, higher BMI categories were associated with stepwise higher odds of rapid decline by eGFRCys, but remained significant only when BMI ≥ 35 kg/m2 (1.87, 1.41 - 2.48). Associations of BMI with incident CKD were insignificant after adjustment. Large WC and WHR were associated with increased risk of rapid decline only by eGFRCys, and of incident CKD only when defined by both filtration markers. Conclusions: Obesity may be a risk factor for kidney function decline, but associations vary by filtration marker used.

Share and Cite:

A. Malkina, R. Katz, M. Shlipak, J. Ix, I. Boer, M. Sarnak, M. Allison, H. Kramer, J. Lin, D. Siscovick and C. Peralta, "Association of Obesity and Kidney Function Decline among Non-Diabetic Adults with eGFR > 60 ml/min/1.73m2: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)," Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 2, 2013, pp. 103-112. doi: 10.4236/ojemd.2013.32016.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. M. Flegal, M. D. Carroll, C. L. Ogden and L. R. Curtin, “Prevalence and Trends in Obesity among US Adults, 1999-2008,” Journal of the American Medical Association, Vol. 303, No. 3, 2010, pp. 235-241. doi:10.1001/jama.2009.2014
[2] T. R. Frieden, “Forward: CDC Health Disparities and Inequalities Report—United States, 2011,” MMWR Surveillance Summaries, Vol. 60, 2011, pp. 1-2.
[3] E. W. Gregg, Y. J. Cheng, B. L. Cadwell, G. Imperatore, D. E. Williams, K. M. Flegal, K. M. Narayan and D. F. Williamson, “Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults,” Journal of the American Medical Association, Vol. 293, No. 15, 2005, pp. 1868-1874. doi:10.1001/jama.293.15.1868
[4] C. Y. Hsu, C. E. McCulloch, C. Iribarren, J. Darbinian and A. S. Go, “Body Mass Index and Risk for End-Stage Renal Disease,” Annals of Internal Medicine, Vol. 144, No. 1, 2006, pp. 21-28. doi:10.7326/0003-4819-144-1-200601030-00006
[5] J. Coresh, E. Selvin, L. A. Stevens, J. Manzi, J. W. Kusek, P. Eggers, F. Van Lente and A. S. Levey, “Prevalence of Chronic Kidney Disease in the United States,” Journal of the American Medical Association, Vol. 298, No. 17, 2007, pp. 2038-2047. doi:10.1001/jama.298.17.2038
[6] R. P. Gelber, T. Kurth, A. T. Kausz, J. E. Manson, J. E. Buring, A. S. Levey and J. M. Gaziano, “Association between Body Mass Index and CKD in Apparently Healthy Men,” American Journal of Kidney Diseases, Vol. 46, No. 5, 2005, pp. 871-880. doi:10.1053/j.ajkd.2005.08.015
[7] H. Kramer, A. Luke, A. Bidani, G. Cao, R. Cooper and D. McGee, “Obesity and Prevalent and Incident CKD: The Hypertension Detection and Follow-Up Program,” American Journal of Kidney Diseases, Vol. 46, No. 4, 2005, pp. 587-594. doi:10.1053/j.ajkd.2005.06.007
[8] C. S. Fox, M. G. Larson, E. P. Leip, B. Culleton, P. W. Wilson and D. Levy, “Predictors of New-Onset Kidney Disease in a Community-Based Population,” Journal of the American Medical Association, Vol. 291, No. 7, 2004, pp. 844-850. doi:10.1001/jama.291.7.844
[9] M. C. Foster, S. J. Hwang, M. G. Larson, J. H. Lichtman, N. I. Parikh, R. S. Vasan, D. Levy and C. S. Fox, “Overweight, Obesity, and the Development of Stage 3 CKD: The Framingham Heart Study,” American Journal of Kidney Diseases, Vol. 52, No. 1, 2008, pp. 39-48. doi:10.1053/j.ajkd.2008.03.003
[10] I. H. de Boer, R. Katz, L. F. Fried, J. H. Ix, J. Luchsinger, M. J. Sarnak, M. G. Shlipak, D. S. Siscovick and B. Kestenbaum, “Obesity and Change in Estimated GFR among Older Adults,” American Journal of Kidney Diseases, Vol. 54, No. 6, 2009, pp. 1043-1051. doi:10.1053/j.ajkd.2009.07.018
[11] N. Noori, F. Hosseinpanah, A. A. Nasiri and F. Azizi, “Comparison of Overall Obesity and Abdominal Adiposity in Predicting Chronic Kidney Disease Incidence among Adults,” Journal of Renal Nutrition, Vol. 19, No. 3, 2009, pp. 228-237. doi:10.1053/j.jrn.2008.11.005
[12] E. F. Elsayed, M. J. Sarnak, H. Tighiouart, J. L. Griffith, T. Kurth, D. N. Salem, A. S. Levey and D. E. Weiner, “Waist-to-Hip Ratio, Body Mass Index, and Subsequent Kidney Disease and Death,” American Journal of Kidney Diseases, Vol. 52, No. 1, 2008, pp. 29-38. doi:10.1053/j.ajkd.2008.02.363
[13] L. A. Stevens, J. Coresh, T. Greene and A. S. Levey, “Assessing Kidney Function—Measured and Estimated Glomerular Filtration Rate,” New England Journal of Medicine, Vol. 354, No. 23, 2006, pp. 2473-2483. doi:10.1056/NEJMra054415
[14] J. H. Ix, I. H. de Boer, C. L. Wassel, M. H. Criqui, M. G. Shlipak and M. A. Whooley, “Urinary Creatinine Excretion Rate and Mortality in Persons with Coronary Artery Disease: The Heart and Soul Study,” Circulation, Vol. 121, No. 11, 2010, pp. 1295-1303. doi:10.1161/CIRCULATIONAHA.109.924266
[15] L. A. Stevens, J. Coresh, C. H. Schmid, H. I. Feldman, M. Froissart, J. Kusek, J. Rossert, F. Van Lente, R. D. Bruce III, Y. L. Zhang, T. Greene and A. S. Levey, “Estimating GFR Using Serum Cystatin C Alone and in Combination with Serum Creatinine: A Pooled Analysis of 3,418 Individuals with CKD,” American Journal of Kidney Diseases, Vol. 51, No. 3, 2008, pp. 395-406. doi:10.1053/j.ajkd.2007.11.018
[16] M. G. Shlipak, M. J. Sarnak, R. Katz, L. F. Fried, S. L. Seliger, A. B. Newman, D. S. Siscovick and C. Stehman-Breen, “Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons,” New England Journal of Medicine, Vol. 352, No. 20, 2005, pp. 2049-2060. doi:10.1056/NEJMoa043161
[17] C. A. Peralta, R. Katz, M. J. Sarnak, J. Ix, L. F. Fried, I. De Boer, W. Palmas, D. Siscovick, A. S. Levey and M. G. Shlipak, “Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications,” Journal of the American Society of Nephrology, Vol. 22, No. 1, 2011, pp. 147-155. doi:10.1681/ASN.2010050483
[18] D. E. Bild, D. A. Bluemke, G. L. Burke, R. Detrano, A. V. Diez Roux, A. R. Folsom, P. Greenland, D. R. Jacob Jr., R. Kronmal, K. Liu, J. C. Nelson, D. O’Leary, M. F. Saad, S. Shea, M. Szklo and R. P. Tracy, “Multi-Ethnic Study of Atherosclerosis: Objectives and Design,” American Journal of Epidemiology, Vol. 156, No. 9, 2002, pp. 871-881. doi:10.1093/aje/kwf113
[19] C. A. Peralta, M. G. Shlipak, S. Judd, M. Cushman, W. McClellan, N. A. Zakai, M. M. Safford, X. Zhang, P. Muntner and D. Warnock, “Detection of Chronic Kidney Disease with Creatinine, Cystatin C, and Urine Albumin-to-Creatinine Ratio and Association with Progression to End-Stage Renal Disease and Mortality,” Journal of the American Medical Association, Vol. 305, No. 15, 2011, pp. 1545-1552. doi:10.1001/jama.2011.468
[20] S. Darouich, R. Goucha, M. H. Jaafoura, S. Zekri, H. Ben Maiz and A. Kheder, “Clinicopathological Characteristics of Obesity-Associated Focal Segmental Glomerulosclerosis,” Ultrastructural Pathology, Vol. 35, No. 4, 2011, pp. 176-182. doi:10.3109/01913123.2011.584657
[21] M. Othman, B. Kawar and A. M. El Nahas, “Influence of Obesity on Progression of Non-Diabetic Chronic Kidney Disease: A Retrospective Cohort Study,” Nephron Clinical Practice, Vol. 113, No. 1, 2009, pp. c16-c23. doi:10.1159/000228071
[22] P. Balakumar, M. K. Arora, J. Reddy and M. B. Anand-Srivastava, “Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism,” Journal of Cardiovascular Pharmacology, Vol. 54, No. 2, 2009, pp. 129-138. doi:10.1097/FJC.0b013e3181ad2190
[23] National Institute of Health, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity, “The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults,” NIH Pulblication No 00-4084, 2000.
[24] Third Report of the National Cholesterol Education Program (NCEP), “Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, Vol. 106, No. 25, 2002, pp. 3143-3421.
[25] A. Molarius, J. C. Seidell, S. Sans, J. Tuomilehto and K. Kuulasmaa, “Waist and Hip Circumferences, and Waist-Hip Ratio in 19 Populations of the WHO MONICA Project,” International Journal of Obesity and Related Metabolic Disorders, Vol. 23, No. 2, 1999, pp. 116-125. doi:10.1038/sj.ijo.0800772
[26] A. S. Levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro III, H. I. Feldman, J. W. Kusek, P. Eggers, F. Van Lente, T. Greene and J. Coresh, “CKD-EPI. A New Equation to Estimate Glomerular Filtration Rate,” Annals of Internal Medicine, Vol. 150, No. 9, 2009, pp. 604-612. doi:10.7326/0003-4819-150-9-200905050-00006
[27] W. F. Clark, J. J. Macnab, J. M. Sontrop, A. K. Jain, L. Moist, M. Salvadori, R. Suri and A. X. Garg, “Dipstick Proteinuria as a Screening Strategy to Identify Rapid Renal Decline,” Journal of the American Society of Nephrology, Vol. 22, No. 9, 2011, pp. 1729-1736. doi:10.1681/ASN.2010111217
[28] D. E. Rifkin, M. G. Shlipak, R. Katz, L. F. Fried, D. Siscovick, M. Chonchol, A. B. Newman and M. J. Sarnak, “Rapid Kidney Function Decline and Mortality Risk in Older Adults,” Archives of Internal Medicine, Vol. 168, No. 20, 2008, pp. 2212-2218. doi:10.1001/archinte.168.20.2212
[29] L. D. Bash, B. C. Astor and J. Coresh, “Risk of Incident ESRD: A Comprehensive Look at Cardiovascular Risk Factors and 17 Years of Follow-Up in the Atherosclerosis Risk in Communities (ARIC) Study,” American Journal of Kidney Diseases, Vol. 55, No. 1, 2010, pp. 31-41. doi:10.1053/j.ajkd.2009.09.006
[30] K. Iseki, Y. Ikemiya, K. Kinjo, T. Inoue, C. Iseki and S. Takishita, “Body Mass Index and the Risk of Development of End-Stage Renal Disease in a Screened Cohort,” Kidney International, Vol. 65, No. 5, 2004, pp. 1870-1876. doi:10.1111/j.1523-1755.2004.00582.x
[31] T. Yoshida, T. Takei, S. Shirota, M. Tsukada, H. Sugiura, M. Itabashi, T. Ogawa, K. Uchida, K. Tsuchiya and K. Nitta, “Risk Factors for Progression in Patients with Early-Stage Chronic Kidney Disease in the Japanese Population,” Internal Medicine, Vol. 47, No. 21, 2008, pp. 1859-1864. doi:10.2169/internalmedicine.47.1171
[32] S. Vupputuri, C. S. Fox, J. Coresh, M. Woodward and P. Muntner, “Differential Estimation of CKD Using Creatinineversus Cystatin C-Based Estimating Equations by Category of Body Mass Index,” American Journal of Kidney Diseases, Vol. 53, No. 6, 2009, pp. 993-1001. doi:10.1053/j.ajkd.2008.12.043
[33] E. L. Knight, J. C. Verhave, D. Spiegelman, H. L. Hillege, D. de Zeeuw, G. C. Curhan and P. E. de Jong, “Factors Influencing Serum Cystatin C Levels Other than Renal Function and the Impact on Renal Function Measurement,” Kidney International, Vol. 65, No. 4, 2004, pp. 1416-1421. doi:10.1111/j.1523-1755.2004.00517.x
[34] P. Muntner, J. Winston, J. Uribarri, D. Mann and C. S. Fox, “Overweight, Obesity, and Elevated Serum Cystatin C Levels in Adults in the United States,” American Journal of Medicine, Vol. 121, No. 4, 2008, pp. 341-348. doi:10.1016/j.amjmed.2008.01.003
[35] S. J. Pinto-Sietsma, G. Navis, W. M. Janssen, D. de Zeeuw, R. O. Gans and P. E. de Jong, “A Central Body Fat Distribution Is Related to Renal Function Impairment, even in Lean Subjects,” American Journal of Kidney Diseases, Vol. 41, No. 4, 2003, pp. 733-741. doi:10.1016/S0272-6386(03)00020-9
[36] P. E. de Jong, J. C. Verhave, S. J. Pinto-Sietsma and H. L. Hillege, “Obesity and Target Organ Damage: The Kidney,” International Journal of Obesity and Related Metabolic Disorders, Vol. 26, Suppl. 4, 2002, pp. S21-S24. doi:10.1038/sj.ijo.0802213

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.